icon-folder.gif   Conference Reports for NATAP  
 
  The International Liver Congress™
EASL - European Association for the
Study of the Liver
Barcelona, Spain
13-17 April 2016
Back grey_arrow_rt.gif
 
 
 
RG-101 IN COMBINATION WITH 4 WEEKS OF ORAL DIRECT ACTING ANTIVIRAL THERAPY ACHIEVES HIGH VIROLOGIC RESPONSE RATES IN TREATMENT NA¤VE GENOTYPE 1 AND 4 CHRONIC HEPATITIS C PATIENTS: INTERIM RESULTS FROM A RANDOMISED, MULTI-CENTER, PHASE 2 STUDY
 
 
  Reported by Jules Levin
EASL 2016 Barcelona April 14-17
 
Gabor Horvath* 1, George Papatheodoridis2, Milotka Fabri3, Mihaly Makara1, Paul Grint4, Michael Huang4, Jacqueline Blem4, Ed Lombardi5
1Buda Hepatology Center, Budapest, Hungary, 2University Gastroenterology Clinic, Medical School of Athens University, Athens, Greece, 3Clinic for Infective Disease, Clinical Center Vojvodina, Novi Sad, Republic of Serbia, 4Regulus Therapeutics, San Diego, 5Agility Clinical, Carlsbad, United States

EASL1

EASL2

EASL3

EASL4

EASL5

EASL6

EASL7

EASL8

EASL9

EASL10

EASL11